Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Clopidogrel BGR (previously Zylagren)“
Suchtreffer
Begriffe & Kennungen
Clopidogrel BGR (previously Zylagren)
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.1 Therapeutic indications · 1
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.3 Contraindications · 1
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section 6.1. S
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · 5 interaction is uncertain. As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · 6 inhibition of CYP2C8 by the glucuronide metabolite of clopidogrel. Due to the risk of increased plasma conce
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · A significantly reduced platelet inhibition has been shown in HIV patients treated with ritonavir-or cobicista
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet agg
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with cl
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · As with other oral P2Y12 inhibitors, co-administration of opioid agonists has the potential to delay and reduc
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Boosted anti-retroviral therapy (ART): HIV patients treated with boosted anti-retroviral therapies (ART) are a
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · CYP2C8 substrate medicinal products: Clopidogrel has been shown to increase repaglinide exposure in healthy vo
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safe
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Heparin: in a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of th
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction i
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole. The pla
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Medicinal products associated with bleeding risk: There is an increased risk of bleeding due to the potential
Eintrag öffnen